Law360, New York (May 13, 2008, 12:00 AM ET) -- The U.S. Federal Trade Commission has served Mylan Inc. with a civil investigative demand related to the drugmaker’s settlement of a patent infringement suit over its generic version of epilepsy treatment Keppra.
Mylan revealed Monday in its quarterly report filed with the U.S. Securities and Exchange Commission that the FTC asked it for more information last month as part of the agency’s investigation into the October settlement struck between Keppra’s manufacturer, UCB Societe Anonyme, and Mylan, along with other defendants.
The FTC initially requested certain materials...
FTC Furthers Probe Into Mylan's Keppra Settlement
To view the full article, take a free trial now.
